A systematic review of myasthenia gravis complicated with myocarditis

Among many of the autoimmune diseases observed in patients with myasthenia gravis (MG), myocarditis is one of the most critical. The goal of this review is to systematically describe and investigate the characteristics of MG complicated with myocarditis. We identified 183 records in PubMed (MEDLINE), Web of Science, and EMBASE from 1948 to September 10, 2020. Studies were included if they presented clinical data on MG complicated with myocarditis. Of the 35 patients from 28 studies in this review, 57.14% (20/35) were males, with a mean age of 59.11 ± 15.87. Dyspnea was the most common cardiac symptom accounting for over 60% in the study. Among the 35 patients, 13 cases of myocarditis occurred concomitantly with MG and the longest interval between MG and myocarditis was 7 years. Forty percent of patients developed myocarditis caused by immune checkpoint inhibitors (ICI). Among the patients with myocarditis, over half of the patients were diagnosed by myocardial biopsy. After active immune regulation and symptomatic treatment, only 15 of 35 patients with MG complicated with myocarditis improved, 18 patients died during hospitalization, one patient died due to tumor progression and 1patient died 5 years later. The prognosis of patients with MG complicated with myocarditis is poor, and myocardial enzymes and other indexes need to be monitored for patients taking ICI drugs. Patients with dyspnea who are still not ideally treated by mechanical ventilation should be vigilant against the occurrence of MG complicated with myocarditis.

[1]  Bihong Zhao,et al.  The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma , 2020, Case reports in immunology.

[2]  S. Sánchez-Ramón,et al.  Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma. , 2020, Hematology/oncology and stem cell therapy.

[3]  S. Vernon,et al.  Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease , 2020, BMJ Case Reports.

[4]  Z. Nahleh,et al.  Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report , 2020, European heart journal. Case reports.

[5]  Biao Zhu,et al.  Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma , 2020, Annals of translational medicine.

[6]  Daiki Kato,et al.  Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report , 2020, Urology case reports.

[7]  Dennis L. Stockdale.  Giant Cell , 2020, Definitions.

[8]  P. van Damme,et al.  Myositis as a neuromuscular complication of immune checkpoint inhibitors , 2020, Acta Neurologica Belgica.

[9]  M. I. Idoate Gastearena,et al.  Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation , 2019, Neuromuscular Disorders.

[10]  Joong-Yang Cho,et al.  Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma. , 2019, Clinical lung cancer.

[11]  Thomopoulou Konstantina,et al.  Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review. , 2019, Lung cancer.

[12]  Shigeaki Suzuki,et al.  Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis , 2019, Scientific Reports.

[13]  Y. Shimizu,et al.  PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis , 2019, Journal of the Neurological Sciences.

[14]  Y. Kiniwa,et al.  Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody. , 2019, European journal of cancer.

[15]  S. Badve,et al.  Giant Cell Polymyositis and Myocarditis in a Patient With Thymoma and Myasthenia Gravis: A Postviral Autoimmune Process? , 2018, Journal of neuropathology and experimental neurology.

[16]  Shigeaki Suzuki,et al.  Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan , 2017, Neurology.

[17]  M. Shintaku,et al.  Chronic myocarditis with a long clinical course: Report of an autopsy case of probable autoimmune myocarditis , 2017, Pathology international.

[18]  Ricky W. Lee,et al.  Myasthenia of the Heart. , 2016, The American journal of medicine.

[19]  D. Hilton,et al.  Giant cell myositis responsive to combined corticosteroids and immunoglobulin , 2015, Practical Neurology.

[20]  A. Verbeek,et al.  The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. , 2015, Journal of neuromuscular diseases.

[21]  K. Kaida,et al.  Cardiac involvements in myasthenia gravis associated with anti‐Kv1.4 antibodies , 2014, European journal of neurology.

[22]  K. Kuwano,et al.  A survival case of invasive thymoma accompanied by acute fulminant myocarditis , 2013, Respirology case reports.

[23]  K. Wakabayashi,et al.  Giant cell polymyositis and myocarditis associated with myasthenia gravis and thymoma , 2013, Neuropathology : official journal of the Japanese Society of Neuropathology.

[24]  H. Sasaki,et al.  Thymoma associated with fatal myocarditis and polymyositis in a 58-year-old man following treatment with carboplatin and paclitaxel: A case report. , 2012, Oncology letters.

[25]  D. Annane,et al.  Percutaneous extracorporeal membrane oxygenation for cardiogenic shock due to acute fulminant myocarditis. , 2010, The Annals of thoracic surgery.

[26]  Shigeaki Suzuki,et al.  Autoimmune targets of heart and skeletal muscles in myasthenia gravis. , 2009, Archives of neurology.

[27]  M. Pincus,et al.  IgG anti-cardiomyocyte antibodies in giant cell myocarditis. , 2008, Annals of clinical and laboratory science.

[28]  Monica Milani,et al.  Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.

[29]  D. V. van Veldhuisen,et al.  Serial right ventricular endomyocardial biopsy in rapid-onset severe heart failure due to giant cell myocarditis. , 2006, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[30]  E. Fadel,et al.  Fatal giant cell myocarditis after thymoma resection in myasthenia gravis. , 2006, The Journal of thoracic and cardiovascular surgery.

[31]  N. Gilhus,et al.  Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. , 2005, Archives of neurology.

[32]  S. Nogawa,et al.  A case report of giant cell myocarditis and myositis observed during the clinical course of invasive thymoma associated with myasthenia gravis. , 2004, The Keio journal of medicine.

[33]  T. Gibson.  The heart in myasthenia gravis. , 1975, American heart journal.

[34]  D. Elmqvist.  Myasthenia Gravis , 1975, The Lancet.

[35]  D. Grob,et al.  Idiopathic giant cell polymyositis. Report of a case and review of the syndrome. , 1974, Archives of neurology.

[36]  M. H. Kaplan,et al.  Antigenic analysis of human heart tissue. Further characterization of an organ-specific antigen of heart tissue. , 1971, Journal of immunology.